Taking people in United StatesNo phase

Testing a daily omega-3 supplement in adults with obesity

Tests SPM Active, a daily omega-3 supplement, in adults with obesity.

Key facts

Who runs it: University of North Carolina, Chapel Hill
Where: Kannapolis, United StatesSee the site
Trial code: NCT06991296
Registry title: Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.
Status: Recruiting
People taking part: 33 people, planned
Started: 2 Jun 2025
Expected to end: Dec 2026
Type of study: Interventional
Treatments tested: SPM Active®
Record updated: 17 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 45 to 60 with obesity. It tests whether taking SPM Active® capsules daily for 12 weeks raises omega-3 fatty acid derivatives in the blood and improves well-being.

Age: 45 to 60 years
Sex: All sexes can join.
Disease stage: Body mass index (BMI) between 30 and 40 kg/m^2.
Earlier treatment: Cannot have used n-3 PUFA supplements, or eaten more than 2 servings of fatty fish per week, in the 3 months before joining. Cannot be on certain medicines (see exclusions).

Main reasons for not taking part

Type 1 or type 2 diabetes
Pregnant or breastfeeding
Active autoimmune disease, liver disease, coagulopathy, or hypothyroidism
Known allergy to fish or shellfish
Active cancer or cancer treatment

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

adults, ages 45-60 years
Body mass index (BMI) between 30 and 40 kg/m\^2
Any race or ethnicity

Who cannot take part

Current use of any of the following medications: asthma controller therapies, anticoagulants, estrogen or testosterone, daily aspirin or NSAIDs
Receiving immunomodulatory or immunosuppressant therapy
Use of n-3 PUFA supplements or high consumption of fatty fish (> 2 servings/week) within 3 months prior to enrollment
Diagnosed type 1 or type 2 diabetes
Active autoimmune disease, liver disease, coagulopathy, or hypothyroidism
Known allergy to fish or shellfish
Known active malignancy or undergoing treatment for malignancy
Age < 45 years or > 60 years
pregnant or breastfeeding women
BMI < 30 kg/m\^2 or > 40 kg/m\^2
Inability to give informed consent

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 45 and 60 years old?

Where in United States

UNC Nutrition Research InstituteKannapolis, United StatesContact: Saroja Voruganti, PHDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if daily supplementation with SPM Active® can increase omega 3 polyunsaturated fatty acid derivatives and improve well-being in adults with obesity. The main questions it aims to answer are:

Read full original descriptionShow less

Does 2 g/day of SPM Active® for 12 weeks increase plasma levels of 14-hydroxydocosahexaenoic (HDHA), 17-HDHA, and 18-hydroxy eicosapentaenoic acid (HEPE)?

Does 2 g/day of SPM Active® for 12 weeks improve self-reported burnout, life satisfaction, and sleep quality?

Participants will:

Take two SPM Active® soft-gel capsules daily for 12 weeks (±2-4 days).

Provide 12-hour fasting blood samples before and after the intervention.

Complete validated surveys on burnout, life satisfaction, and sleep quality at baseline and study end.

The group in the trial

SPM Active® SupplementationTreatment being tested
All participants will take two SPM Active® soft-gel capsules daily (total 2 g/day) for 12 weeks (± 2-4 days). Fasting blood samples will be drawn at baseline and at end-of-treatment to quantify 14-HDHA, 17-HDHA, and 18-HEPE levels. Validated surveys assessing burnout, life satisfaction, and sleep quality will be administered before and after the supplementation period.
Treatment: SPM Active®